Advances in inhaled corticosteroid pharmacology

Allergy and Asthma Proceedings

Volumn 28, Issue 2, 2007, Pages 114-124

  Zitt, Myron J ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b Queens Long Island Medical Group   (United States)

Author keywords

Asthma; Asthma therapy; Ciclesonide; Corticosteroid therapy; Efficacy; Inflammatory disease; Lung function; Remodeling; Safety; Therapeutic index

Indexed keywords

ANTIASTHMATIC AGENT; CICLESONIDE; CORTICOSTEROID; PREGNANE DERIVATIVE;

ASTHMA; BREATHING MECHANICS; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; LUNG VENTILATION; PATHOPHYSIOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES; PREGNENEDIONES; PULMONARY VENTILATION; RESPIRATORY FUNCTION TESTS; RESPIRATORY MECHANICS; TREATMENT OUTCOME;

EID: 34248349125     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2007.28.2989     Document Type: Conference Paper

References (61)

1. Martinez FD. Present and future treatment of asthma in infants and young children. J Allergy Clin Immunol 104:169-174, 1999.
2. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343:1054-1063, 2000.
3. Guilbert TW, Morgan WJ, Krawiec M, et al. The prevention of early asthma in kids study: Design, rationale, and methods for the Childhood Asthma Research and Education network. Control Clin Trials 25:286-310, 2004.
4. Peat JK, Woolcock AJ, and Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis. 70:171-179, 1987.
5. Davies DE, Wicks J, Powell RM, et al. Airway remodeling in asthma: New insights. J Allergy Clin Immunol 111:215-225, 2003.
6. Vonk JM, Jongepier H, Panhuysen CI, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 58:322-327, 2003.
7. Selroos O, Pietinalho A, Lofroos AB, and Riska H. Effect of early vs. late intervention with inhaled corticosteroids in asthma. Chest. 108:1228-1234, 1995.
8. Agertoft L, and Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 88:373-381, 1994.
9. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 354:1985-1997, 2006.
10. Murray CS, Woodcock A, Langley SJ, et al. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): Double-blind, randomised, controlled study. Lancet 368(9537):754-762, 2006.
11. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 130:487-495, 1999.
12. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109:410-418, 2002.
13. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 170:836-844, 2004.
14. Covar RA, Spahn JD, Murphy JR, et al. Progression of asthma measured by lung function in the childhood asthma management program. Am J Respir Crit Care Med 170:234-241, 2004.
15. Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 13:1353-1359, 2004.
16. Payne DN, Rogers AV, Adelroth E, et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Respir Crit Care Med 167:78-82, 2003.
17. Chetta A, Foresi A, Del Donno M, et al. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 111:852-857, 1997.
18. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160:1001-1008, 1999.
19. Jenkins HA, Cool C, Szefler SJ, et al. Histopathology of severe childhood asthma: A case series. Chest 124:32-41, 2003.
20. Laitinen LA, Laitinen A, and Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 90:32-42, 1992.
21. Jeffrey PK, Godfrey RW, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. Am Rev Respir Dis 145:890-899, 1992.
22. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 109(Suppl):S447-S460, 2002.
23. Kraft M. The distal airways: Are they important in asthma? Eur Respir J 14:1403-1417, 1999.
24. Tashkin DP. The role of small airway inflammation in asthma. Allergy Asthma Proc 23:233-242, 2002.
25. Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: Direct measurement of intrabronchial pressure. J Appl Physiol 72:1016-1023, 1992.
26. Thongngarm T, Silkoff PE, Kossack WS, and Nelson HS. Hydrofluoroalkane- 134A beclomethasone or chlorofluorocarbon fluticasone: Effect on small airways in poorly controlled asthma. J Asthma 42:257-263, 2005.
27. Barnes PJ, Pedersen S, and Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157:S1-S53, 1998.
28. Barnes PJ, and Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 139:359-370, 2003.
29. Welch MJ, Levy S, Smith JA, et al. Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. Chest 112:597-606, 1997.
30. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 159:1043-1051, 1999.
31. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 352:2163-2173, 2005.
32. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet 360:1715-1721, 2002.
33. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: A pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 44:37-47, 2004.
34. Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 106:1209-1226, 2000.
35. Reynolds NA, and Scott LJ. Ciclesonide. Drugs 64:511-519, 2004.
36. Yang TT, Li S, Wyka B, et al. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med. 14:487-494, 2001.
37. Rohtagi S, Appajosyuala S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: A pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 44:37-47, 2004.
38. Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 51:400-409, 2001.
39. Thorsson L, Edsbacker S, Kallen A, et al Pharmacokinetics and systemic activity of fluticasone via diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 52:529-538, 2001.
40. Rohatagi S, Bye A, Falcoz C, et al. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 36:938-941, 1996.
41. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 91(Suppl):22-28, 1997.
42. Pearlman DS, Berger WE, Kerwin E, et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 116:1206-1212, 2005.
43. Ukena D, Biberger C, Steinijans V, et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther 2006. doi:10.1016/j.pupt.2006.05.007
44. Busse W, Kaliner M, Bernstein D, et al. The novel corticosteroid ciclesonide is efficacious and has a favorable safety profile in adults and adolescents with severe persistent asthma. J Allergy Clin Immunol 115(Suppl):S213, 2005.
45. Nayak A, Charous BL, Finn A, et al. A novel inhaled corticosteroid ciclesonide significantly improves quality of life in patients with mild-to-moderate asthma. J Allergy Clin Immunol 115(Suppl):S210, 2005.
46. Niphadkar P, Jagannath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160 mg qd and budesonide 200 mg bid in adults with persistent asthma: A phase III, randomized, doubledummy, open-label study. Clin Ther 27:1752-1763, 2005.
47. Hansel TT, Benezet O, Kafe H, et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther 28:906-920, 2006.
48. Engelstätter R, Banerji D, Steinijans VW, et al. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide: Results from a polled analysis. Am J Respir Crit Care Med 167:abstract A1511, 2003. (Am J Respir Crit Care Med 169S:A92, 2004)
49. Chapman KR, Patel P, Boulet LP, et al. Efficacy and long term safety of ciclesonide in asthmatic patients as demonstrated in a 52-week long study. Eur Respir J Abs 2328;20(S38):S373-S274, 2002.
50. Korenblat P, Bernstein D, Fish J, et al. Ciclesonide HFA-MDI has a lower incidence of oral candidiasis than beclomethasone dipropionate HFA-MDI in patients with severe persistent asthma: Results of a long-term study. Ann Allergy Asthma Immunol 94:173, 2005.
51. Bernstein JA, Noonan MJ, Rim C, et al. Ciclesonide has minimal oropharyngeal side effects in the treatment of patients with moderate-to-severe asthma. JACI 113, 2:3113, 2004.
52. Postma DS, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur J Respir 17:1083-1088, 2001.
53. Szefler S, Rohatagi S, and Williams J. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 128:1104-1114, 2005.
54. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 87:2160-2163, 2002.
55. Derom E, Van De Velde V, Marissens S, et al.. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Pulm Pharmacol Ther 18:328-336, 2005.
56. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma, Ann Allergy Asthma Immunol 94:465-472, 2005.
57. Agertoft L, and Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 115:940-945, 2005.
58. Skoner D, Maspero J, Kundu, S, et al. Ciclesonide administered once daily has no effect on growth velocity in prepubertal children with mild, persistent asthma. JACI 117(Suppl 1):S11, 2006.
59. Derendorf H. Corticosteroid pharmacokinetic/pharmacodynamic parameters and their relationship to safety and efficacy. Allergy Asthma Proc 26:327-335, 2005.
60. Derendorf H, and Hochhaus G. What is the best marker for inhaled corticosteroid safety? Allergy Asthma Proc 26:89-93, 2005.
61. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 332: 868-875, 1995.